Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
Zacks Investment Research | May 04, 2017 11:06PM ET
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
Conatus’ shares have outperformed the Zacks classified Medical Products industry so far this year. Shares of the company gained 46.5% while the industry registered an increase of 14.4%.
Conatus has no approved product in its portfolio at the moment. However, the company recognized $7.0 million as collaboration revenues for the first quarter of 2017. It also beat the Zacks Consensus Estimate of $5.88 million. The collaboration revenues were related to an agreement with Novartis AG (NYSE:NVS) , which was inked in Dec 2016, for the worldwide development and commercialization of Conatus’ lead candidate, emricasan, as a single agent treatment for NASH (Nonalcoholic steatohepatitis) cirrhosis in both compensated and decompensated patients. As a part of the deal, Novartis will share 50% cost of four ongoing phase IIb clinical trials on emricasan.
In the first quarter, research and development expenses were $7.9 million, up 68% from the year-ago quarter. This was mainly due to cost related to the ongoing Encore study. General and administrative expenses were $2.8 million, up 7.7% from the year-ago quarter. This was primarily due to an increase in personnel costs partially offset by lower consulting fees.
The company has raised $15 million from Novartis by issuing a convertible promissory note.It anticipates another $7 million as Novartis exercises its option to an exclusive license for the global development and commercialization of emricasan in May 2017.
Emricasan in Focus
Emricasan is being developed for the treatment of patients with chronic liver disease.
With the initiation of the ENCORE-LF clinical trial in May 2017, there are four ongoing emricasan Phase IIb clinical trials. The ENCORE-LF (Liver Function) is a placebo-controlled phase IIb study evaluating twice-daily treatment with emricasan for preventing or delaying the clinical outcomes associated with the progression of advanced liver disease in 210 patients with decompensated NASH cirrhosis. Data from this 48-week study are expected in 2019.
In Nov 2016, Conatus initiated a placebo-controlled, phase IIb study, evaluating the effect of emricasan for the reduction of hepatic venous pressure gradient (HVPG) in patients with compensated or early decompensated liver cirrhosis caused by NASH, and severe portal hypertension confirmed by HVPG of ≥12 mmHg at baseline. Data after 24 weeks of twice-daily treatment with emricasan or placebo are anticipated in 2018.
The company is conducting two additional phase IIb studies on emricasan. These include the POLT-HCV-SVR study evaluating potential improvements in Ishak fibrosis score in post-orthotropic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant caused by recurrent hepatitis C virus (HCV) infection in those who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy. Data are expected in the first half of 2018.
ENCORE-NF is the other study evaluating potential improvements in fibrosis and steatohepatitis in patients with fibrosis caused by NASH. Results are expected in 2018.
The company also plans to initiate a new study - ENCORE-XT - on emricasan under the ENCORE program.
We expect investor focus to remain on updates pertaining to the candidate’s development.
Guidance
Cash, cash equivalents and marketable securities are expected between $45 million and $55 million by year-end 2017.
Conatus expects its current financial resources, together with the anticipated license option exercise milestone payment and expense reimbursements related to the Novartis agreement, to be sufficient for continuing operations through the end of 2019.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.